Systemic and mucosal immunity to respiratory syncytial virus induced by recombinant Streptococcus gordonii surface-displaying a domain of viral glycoprotein G

FEMS Immunology and Medical Microbiology

Volumn 48, Issue 1, 2006, Pages 116-122

  Falcone, Valeria ^a   Mihm, Dagmar ^a   Neumann Haefelin, Dieter ^a   Costa, Caterina ^b   Nguyen, Thien ^c   Pozzi, Gianni ^b   Ricci, Susanna ^b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF SIENA   (Italy)

^c INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

Glycoprotein G; Mucosal immunity; Respiratory syncytial virus; Streptococcus gordonii

Indexed keywords

GLYCOPROTEIN GP 130; GLYCOPROTEIN GP 140; GLYCOPROTEIN GP 160; GP 1385; GP 246; IMMUNOGLOBULIN G; MICROSOMAL AMINOPEPTIDASE; THROMBOSPONDIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CELL SURFACE; CONTROLLED STUDY; FEMALE; IMMUNIZATION; IMMUNOGLOBULIN BLOOD LEVEL; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; STREPTOCOCCUS GORDONII; VIRUS INDUCTION; VIRUS INFECTION; VIRUS REPLICATION;

ANIMALS; ANTIBODIES, VIRAL; DRUG DELIVERY SYSTEMS; GENE PRODUCTS, ENV; IMMUNITY, MUCOSAL; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; RESPIRATORY SYNCYTIAL VIRUSES; RESPIROVIRUS INFECTIONS; STREPTOCOCCUS; VACCINES, SYNTHETIC; VIRAL VACCINES;

EID: 33748605901     PISSN: 09288244     EISSN: 1574695X     Source Type: Journal    
DOI: 10.1111/j.1574-695X.2006.00130.x     Document Type: Article

References (29)

1. Beninati C, Oggioni MR, Boccanera M et al. (2000) Therapy of mucosal candidiasis by expression of an anti-idiotype in human commensal bacteria. Nat Biotechnol 18: 1060-1064.
2. Brandenburg AH, Neijens HJ & Osterhaus AD (2001) Pathogenesis of RSV lower respiratory tract infection: implications for vaccine development. Vaccine 19: 2769-2782.
3. Cano F, Plotnicky-Gilquin H, Nguyen TN, Liljeqvist S, Samuelson P, Bonnefoy J, Ståhl S & Robert A (2000) Partial protection to respiratory syncytial virus (RSV) elicited in mice by intranasal immunization using live staphylococci with surface-displayed RSV-peptides. Vaccine 18: 2743-2752.
4. Collins PL, Chanock RM & Murphy BR (2001) Respiratory syncytial virus. Fields Virology, Vol 1. (Knipe DM, Howly PM, Griffin DM, Lamb RA, Martin MA, Roizman B & Straus SE, eds), pp. 1443-1485. Lippincot Williams & Wilkins, Philadelphia (PA).
5. Corvaia N, Tournier P, Nguyen TN, Haeuw JF, Power UF, Binz H & Andreoni C (1997) Challenge of BALB/c mice with respiratory syncytial virus does not enhance the Th2 pathway induced after immunization with a recombinant G fusion protein, BBG2NA, in aluminum hydroxide. J Infect Dis 176: 560-569.
6. Giomarelli B, Provvedi R, Meacci F, Maggi T, Medaglini D, Pozzi G, Mori T, McMahon JB, Gardella R & Boyd MR (2002) The microbicide cyanovirin-N expressed on the surface of commensal bacterium Streptococcus gordonii captures HIV-1. Aids 16: 1351-1356.
7. Goetsch L, Plotnicky-Gilquin H, Champion T, Beck A, Corvaia N, Ståhl S, Bonnefoy JY, Nguyen TN & Power UF (2000) Influence of administration dose and route on the immunogenicity and protective efficacy of BBG2Na, a recombinant respiratory syncytial virus subunit vaccine candidate. Vaccine 18: 2735-2742.
8. Karron RA, Wright PF, Belshe RB et al. (2005) Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants. J Infect Dis 191: 1093-1104.
9. Kim HW, Canchola JG & Brandt CD (1969) Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 89: 422-434.
10. Kotloff KL, Wasserman SS, Jones KF, Livio S, Hruby DE, Franke CA & Fischetti VA (2005) Clinical and microbiological responses of volunteers to combined intranasal and oral inoculation with a Streptococcus gordonii carrier strain intended for future use as a group A streptococcus vaccine. Infect Immun 73: 2360-2366.
11. Maggi T, Oggioni MR, Medaglini D, Bianchi Bandinelli ML, Soldateschi D, Wiesmuller KH, Muller CP, Valensin PE & Pozzi G (2000) Expression of measles virus antigens in Streptococcus gordonii. New Microbiol 23: 119-128.
12. Maggi T, Spinosa M, Ricci S, Medaglini D, Pozzi G & Oggioni MR (2002) Genetic engineering of Streptococcus gordonii for the simultaneous display of two heterologous proteins at the bacterial surface. FEMS Microbiol Lett 210: 135-141.
13. Medina E & Guzman CA (2001) Use of live bacterial vaccine vectors for antigen delivery: potential and limitations. Vaccine 19: 1573-1580.
14. Murphy BR & Collins PL (2002) Live-attenuated virus vaccines for respiratory syncytial and parainfluenza viruses: applications of reverse genetics. J Clin Invest 110: 21-27.
15. Oggioni MR & Pozzi G (1996) A host-vector system for heterologous gene expression in Streptococcus gordonii. Gene 169: 85-90.
16. Oggioni MR, Medaglini D, Romano L et al. (1999) Antigenicity and immunogenicity of the V3 domain of HIV type 1 glycoprotein 120 expressed on the surface of Streptococcus gordonii. AIDS Res Human Retroviruses 15: 451-459.
17. Ostler T & Ehl S (2002) A cautionary note on experimental artefacts induced by fetal calf serum in a viral model of pulmonary eosinophilia. J Immunol Methods 268: 211-218.
18. Plotnicky-Gilquin H, Cyblat-Chanal D, Goetsch L et al. (2002) Passive transfer of serum antibodies induced by BBG2Na, a subunit vaccine, in the elderly protects SCID mouse lungs against respiratory syncytial virus challenge. Virology 303: 130-137.
19. Polack FP & Karron RA (2004) The future of respiratory syncytial virus vaccine development. Pediatr Infect Dis J 23: S65-S73.
20. Power UF, Plotnicky-Gilquin H, Huss T, Robert A, Trudel M, Stahl S, Uhlen M, Nguyen TN & Binz H (1997) Induction of protective immunity in rodents by vaccination with a prokaryotically expressed recombinant fusion protein containing a respiratory syncytial virus G protein fragment. Virology 230: 155-166.
21. Power UF, Huss T, Michaud V, Plotnicky-Gilquin H, Bonnefoy JY & Nguyen TN (2001a) Differential histopathology and chemokine gene expression in lung tissues following respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV- or BBG2Na-immunized mice. J Virol 75: 12421-12430.
22. Power UF, Nguyen TN, Rietveld E et al. (2001b) Safety and immunogenicity of a novel recombinant subunit respiratory syncytial virus vaccine (BBG2Na) in healthy young adults. J Infect Dis 184: 1456-1460.
23. Pozzi G, Musmanno RA, Lievens PM, Oggioni MR, Plevani P & Manganelli R (1990) Method and parameters for genetic transformation of Streptococcus sanguis Challis. Res Microbiol 141: 659-670.
24. Pozzi G, Contorni M, Oggioni MR, Manganelli R, Tommasino M, Cavalieri F & Fischetti VA (1992) Delivery and expression of a heterologous antigen on the surface of streptococci. Infect Immun 60: 1902-1907.
25. Pozzi G, Oggioni MR, Manganelli R, Medaglini D, Fischetti VA, Fenoglio D, Valle MT, Kunkl A & Manca F (1994) Human T-helper cell recognition of an immunodominant epitope of HIV-1 gp120 expressed on the surface of Streptococcus gordonii. Vaccine 12: 1071-1077.
26. Pozzi G, Oggioni MR & Medaglini D (1997) Recombinant Streptococcus gordonii as live vehicle for vaccine antigens. Gram-Positive Bacteria. Vaccine Vehicles for Mucosal Immunization (Pozzi G & Wells JM, eds), pp. 35-60. Springer Verlag/Landes Bioscience, New York/Georgetown, TX.
27. Ricci S, Macchia G, Ruggiero P et al. (2003) In vivo mucosal delivery of bioactive human interleukin 1 receptor antagonist produced by Streptococcus gordonii. BMC Biotechnol 3: 15-25.
28. Shaw DM, Gaerthe B, Leer RJ et al. (2000) Engineering the microflora to vaccinate the mucosa: serum immunoglobulin G responses and activated draining cervical lymph nodes following mucosal application of tetanus toxin fragment C-expressing lactobacilli. Immunology 100: 510-518.
29. Ståhl S, Robert A, Gunneriusson E, Wernerus H, Cano F, Liljeqvist S, Hansson M, Nguyen TN & Samuelson P (2000) Staphylococcal surface display and its applications. Int J Med Microbiol 290: 571-577.